Afshari Amir R, Sanati Mehdi, Kesharwani Prashant, Sahebkar Amirhossein
Department of Physiology and Pharmacology, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Birjand University of Medical Sciences, Birjand, Iran.
J Funct Biomater. 2023 Aug 2;14(8):408. doi: 10.3390/jfb14080408.
Standard cancer chemotherapeutics often produce significant adverse effects and eventually lose their effectiveness due to the emergence of resistance mechanisms. As a result, patients with malignant tumors experience a poor quality of life and a short lifespan. Thus, combination medication regimens provide various advantages, including increased success rate, fewer side effects, and fewer occurrences of resistance. Curcumin (Cur), a potential phytochemical from turmeric, when coupled with traditional chemotherapeutics, has been established to improve the effectiveness of cancer treatment in clinical and preclinical investigations. Cur not only exerts multiple mechanisms resulting in apoptotic cancer cell death but also reduces the resistance to standard chemotherapy drugs, mainly through downregulating the multi-drug resistance (MDR) cargoes. Recent reports showed the beneficial outcomes of Cur combination with many chemotherapeutics in various malignancies. Nevertheless, owing to the limited bioavailability, devising co-delivery strategies for Cur and conventional pharmaceuticals appears to be required for clinical settings. This review summarized various Cur combinations with standard treatments as cancer therapeutics.
标准的癌症化疗药物通常会产生显著的副作用，并且由于耐药机制的出现最终会失去疗效。因此，患有恶性肿瘤的患者生活质量差且寿命短。因此，联合用药方案具有多种优势，包括提高成功率、减少副作用以及降低耐药性的发生。姜黄素（Cur）是一种从姜黄中提取的潜在植物化学物质，在临床和临床前研究中，当与传统化疗药物联合使用时，已被证实可提高癌症治疗的效果。Cur不仅通过多种机制导致癌细胞凋亡死亡，还主要通过下调多药耐药（MDR）转运蛋白来降低对标准化疗药物的耐药性。最近的报告显示了Cur与多种化疗药物联合应用于各种恶性肿瘤的有益效果。然而，由于生物利用度有限，在临床环境中似乎需要设计Cur与传统药物的共递送策略。本综述总结了Cur与标准治疗联合作为癌症治疗方法的各种情况。
